These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19277712)

  • 21. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
    Brandes AA; Basso U; Reni M; Vastola F; Tosoni A; Cavallo G; Scopece L; Ferreri AJ; Panucci MG; Monfardini S; Ermani M;
    J Clin Oncol; 2004 May; 22(9):1598-604. PubMed ID: 15117981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. VEGF isoforms as outcome biomarker for anti-angiogenic therapy in recurrent glioblastoma.
    D'Alessandris QG; Martini M; Cenci T; Capo G; Ricci-Vitiani L; Larocca LM; Pallini R
    Neurology; 2015 May; 84(18):1906-8. PubMed ID: 25862796
    [No Abstract]   [Full Text] [Related]  

  • 23. Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme.
    Oudard S; Carpentier A; Banu E; Fauchon F; Celerier D; Poupon MF; Dutrillaux B; Andrieu JM; Delattre JY
    J Neurooncol; 2003 May; 63(1):81-6. PubMed ID: 12814259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.
    Groves MD; Puduvalli VK; Gilbert MR; Levin VA; Conrad CA; Liu VH; Hunter K; Meyers C; Hess KR; Alfred Yung WK
    Br J Cancer; 2009 Aug; 101(4):615-20. PubMed ID: 19672263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.
    Groves MD; Puduvalli VK; Hess KR; Jaeckle KA; Peterson P; Yung WK; Levin VA
    J Clin Oncol; 2002 Mar; 20(5):1383-8. PubMed ID: 11870183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.
    Lassen U; Chinot OL; McBain C; Mau-Sørensen M; Larsen VA; Barrie M; Roth P; Krieter O; Wang K; Habben K; Tessier J; Lahr A; Weller M
    Neuro Oncol; 2015 Jul; 17(7):1007-15. PubMed ID: 25665807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
    Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
    J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.
    Schiff D; Jaeckle KA; Anderson SK; Galanis E; Giannini C; Buckner JC; Stella P; Flynn PJ; Erickson BJ; Schwerkoske JF; Kaluza V; Twohy E; Dancey J; Wright J; Sarkaria JN
    Cancer; 2018 Apr; 124(7):1455-1463. PubMed ID: 29313954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.
    Erdem-Eraslan L; van den Bent MJ; Hoogstrate Y; Naz-Khan H; Stubbs A; van der Spek P; Böttcher R; Gao Y; de Wit M; Taal W; Oosterkamp HM; Walenkamp A; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; van der Holt B; Vernhout RM; Sillevis Smitt PA; Kros JM; French PJ
    Cancer Res; 2016 Feb; 76(3):525-34. PubMed ID: 26762204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
    Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
    Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
    Badruddoja MA; Pazzi M; Sanan A; Schroeder K; Kuzma K; Norton T; Scully T; Mahadevan D; Ahmadi MM
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):715-721. PubMed ID: 28808777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.
    Iwamoto FM; Abrey LE; Beal K; Gutin PH; Rosenblum MK; Reuter VE; DeAngelis LM; Lassman AB
    Neurology; 2009 Oct; 73(15):1200-6. PubMed ID: 19822869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
    Chamberlain MC
    Expert Rev Neurother; 2012 Aug; 12(8):929-36. PubMed ID: 23002937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined chemotherapy with temozolomide and fotemustine in recurrent glioblastoma patients.
    Gaviani P; Salmaggi A; Silvani A
    J Neurooncol; 2011 Sep; 104(2):617-8. PubMed ID: 21229293
    [No Abstract]   [Full Text] [Related]  

  • 35. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma.
    Norden AD; Drappatz J; Muzikansky A; David K; Gerard M; McNamara MB; Phan P; Ross A; Kesari S; Wen PY
    J Neurooncol; 2009 Apr; 92(2):149-55. PubMed ID: 19043778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
    Minniti G; Amelio D; Amichetti M; Salvati M; Muni R; Bozzao A; Lanzetta G; Scarpino S; Arcella A; Enrici RM
    Radiother Oncol; 2010 Dec; 97(3):377-81. PubMed ID: 20855119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-Angiogenics: Their Role in the Treatment of Glioblastoma.
    Winkler F; Osswald M; Wick W
    Oncol Res Treat; 2018; 41(4):181-186. PubMed ID: 29562225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of avastin in the management of recurrent glioblastoma.
    Sweet JA; Feinberg ML; Sherman JH
    Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?
    Blumenthal DT; Mendel L; Bokstein F
    J Neurooncol; 2016 May; 127(3):493-502. PubMed ID: 26721244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.
    Zhang G; Huang S; Wang Z
    J Clin Neurosci; 2012 Dec; 19(12):1636-40. PubMed ID: 23047061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.